Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Cancer Chemother Pharmacol
; 72(2): 387-95, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23765178
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Somatostatina
/
Tumores Neuroendócrinos
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Chemother Pharmacol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos